{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","name":"Research Synthesis: Telomere Effects — full paper","doi":"10.17605/OSF.IO/4RSMW","doi_status":"minted","osf_url":"https://osf.io/4rsmw/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_acbbf4c2352d4ebc/chain","content_hash":"sha256:c177226449a619ef6c04cac19cd800c090db224b43176ccee329bde33b64cc4e","provenance_passport":{"publication_id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","submission_id":"1cbf6d26-14af-4966-a0e7-87bf6db5eb5c","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:c177226449a619ef6c04cac19cd800c090db224b43176ccee329bde33b64cc4e","persistent_identifiers":{"doi":"10.17605/OSF.IO/4RSMW","osf_url":"https://osf.io/4rsmw/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_acbbf4c2352d4ebc","dw_chain_url":"https://provenance.researka.org/artifacts/claim_acbbf4c2352d4ebc/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","object_type":"publication","parent_object_id":"1cbf6d26-14af-4966-a0e7-87bf6db5eb5c","title":"Research Synthesis: Telomere Effects — full paper","body_markdown":"# Research Synthesis: Telomere Effects — full paper\n\n## Abstract\n\nEvidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.\n\nThis synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.\n\nTelomere length is widely examined as a biomarker of biological aging, yet the clinical implications of observed associations remain uncertain.\n\nWe conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes.\n\nThe current evidence supports telomere length as a reproducible prognostic marker for cancer recurrence and diabetes complications, but its value as a therapeutic target remains unproven; interventions that lengthen telomeres have not yet demonstrated downstream clinical benefit, and mechanistic plausibility alone is insufficient to justify routine clinical application.\n\n**Evidence-abstraction note.** The 40 retained reference papers are not 40 independent primary clinical trials: 40 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_effects-v06-DAILY-2026-06-04T09-26-23Z-R2`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-04.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `telomere effects aging`\n- `telomere effects older adults`\n- `telomere effects randomized controlled trial`\n- `telomere aging`\n- `telomere older adults`\n- `telomere randomized controlled trial`\n\n### Eligibility criteria\n- Sources whose primary content addresses telomere effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 172 records in the receipt-candidate union, 52 were classified as source candidates and 40 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 172 |\n| Classified source candidates | 52 |\n| No extractable claims | 22 |\n| None-only claim binding | 9 |\n| Mixed partial-or-none claim-binding candidates | 63 |\n| Partial-only claim-binding candidates | 23 |\n| Strict high-confidence sources | 3 |\n| Admitted final sources | 40 |\n\n### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=23; claims=739 | no extracted directional signal in 19/23 sources | 13 indirect; 10 review | limited corpus depth in this outcome class |\n| Immune and Inflammation | n=5; claims=214 | no extracted directional signal in 5/5 sources | 3 indirect; 2 review | limited corpus depth in this outcome class |\n| Mortality and Survival | n=3; claims=235 | no extracted directional signal in 2/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |\n| Safety and Comorbidity | n=3; claims=75 | no extracted directional signal in 3/3 sources | 3 indirect | limited corpus depth in this outcome class |\n| Cardiometabolic | n=2; claims=73 | no extracted directional signal in 2/2 sources | 2 review | limited corpus depth in this outcome class |\n| Dosing and Pharmacokinetics | n=1; claims=24 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Frailty | n=1; claims=7 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Longevity | n=1; claims=36 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n| Muscle Function | n=1; claims=14 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n\nThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.\n\n### Contextual Adjacent Evidence Outcomes\n\n23 included sources were assigned to this outcome class. Directional coding: mixed=1, null=19, unclear=3. Directness coding: indirect=13, review=10.\n\n### Immune Inflammation Outcomes\n\n5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, review=2.\n\n### Mortality Survival Outcomes\n\n3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=2, review=1.\n\n### Safety Comorbidity Outcomes\n\n3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.\n\n### Cardiometabolic Outcomes\n\n2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.\n\n### Dosing Pharmacokinetics Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n### Frailty Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n### Longevity Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.\n\n### Muscle Function Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus is dominated by observational cohort designs and systematic reviews of observational data; no large, long-duration randomized controlled trial of telomere-targeted intervention with hard clinical endpoints such as all-cause mortality or incident cardiovascular events was identified within the included sources. Because the corpus lacks a mortality-focused intervention trial, the synthesis cannot adjudicate whether telomere elongation translates into survival benefit. This gap leaves the headline conclusion that telomere biology is a viable anti-aging target resting on mechanistic plausibility and associative data rather than causal trial evidence.\n\nThe enrolled populations constrain external validity in important ways. Children, pregnant women outside the Gemmati 2025 miscarriage cohort, and adults of non-European ancestry are largely absent from the included studies. Findings therefore may not generalize to populations with different metabolic phenotypes, age profiles, or ethnic backgrounds, and subgroup effects (for example, by sex or genotype, as explored by Kim 2025) remain underpowered.\n\nThe evidence base is heavily weighted toward telomere length as a surrogate biomarker, while functional and patient-centered endpoints are sparse. Whether telomere length itself is a valid surrogate or merely a correlate of underlying biological aging processes remains unresolved — a concern consistent with the general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). In parallel, the exercise meta-analyses (Sanchez-Gonzalez 2024, Sanchez-Gonzalez 2025) found that intervention heterogeneity in duration and modality accounted for significant variance, yet no included study reported dose-response thresholds for clinically actionable telomere preservation. The mechanism-to-clinic gap is therefore wide: the corpus documents consistent cross-sectional and short-term mechanistic associations but cannot confirm that intervening on telomere biology improves downstream health trajectories.\n\n## Conclusion\n\nFor telomere effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\n## What This Synthesis Adds\n\nThis synthesis maps 40 included sources on Telomere Effects across 9 outcome classes and 270 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 40 curated reference papers, the evidence base for Telomere Effects shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nThe strongest unresolved contrast is the disagreement between Sanchez-Gonzalez 2024 and Young 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.\n\nPrior reviews in the corpus (Sanchez-Gonzalez 2024) emphasize convergent signals on Telomere Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 1 | null | direct interventional hard-endpoint gap |\n| cardiometabolic | 0 | 2 | null | direct interventional hard-endpoint gap |\n| frailty | 0 | 1 | null | direct interventional hard-endpoint gap |\n| muscle function | 0 | 1 | null | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 0 | 23 | mixed, null, unclear | conflict-resolution gap |\n| mortality and survival | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |\n| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 5 | null | direct interventional hard-endpoint gap |\n| safety and comorbidity | 0 | 3 | null | direct interventional hard-endpoint gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |\n| P3 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P4 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P5 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 23 indirect sources; direction profile: mixed, null, unclear |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Telomere Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Sanchez-Gonzalez 2024; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.01.\n- Young 2025; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001.\n- Sasmita 2025; Observational; tier=B2; directness=review; N=—; population=—; endpoint=mortality survival; direction=null; representative statistic=P = 0.01.\n- Su 2025; Observational; tier=B2; directness=review; N=—; population=—; endpoint=immune inflammation; direction=null; representative statistic=P < 0.00001.\n- Jaeger 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.004.\n- Yang 2025; Observational; tier=B2; directness=indirect; N=—; population=type 2 diabetes patients; endpoint=mortality survival; direction=null; representative statistic=P < 0.001.\n- Ojeda-Rodriguez 2024; Observational; tier=B2; directness=review; N=—; population=type 2 diabetes patients; endpoint=cardiometabolic; direction=null; representative statistic=P < 0.05.\n- Wolkowitz 2011; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=null; representative statistic=P < 0.01.\n- Fuente 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.\n- Gemmati 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.000001.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\n- Severity 4 disagreement: Sanchez-Gonzalez 2024 vs Young 2025; Sanchez-Gonzalez 2024 (unclear) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Xia 2024 vs Young 2025; Xia 2024 (unclear) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Fu 2024 vs Young 2025; Fu 2024 (null) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Al-Hawary 2024 vs Young 2025; Al-Hawary 2024 (null) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Hastings 2024 vs Young 2025; Hastings 2024 (null) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Andreikos 2024 vs Young 2025; Andreikos 2024 (null) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Jaeger 2024 vs Young 2025; Jaeger 2024 (null) vs Young 2025 (mixed) on contextual other\n- Severity 4 disagreement: Sanchez-Gonzalez 2025 vs Young 2025; Sanchez-Gonzalez 2025 (null) vs Young 2025 (mixed) on contextual other\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Mutz 2024, Farhat 2025, Ishii 2025, Wattanathorn 2025, Wilbourn 2018, Murillo-Ortiz 2025, Ismail 2025, Guillen-Parra 2024, Liu 2025, Lehodey 2025, Parikh 2025, Liu 2025b, Breitling 2016, Sun 2025, Hanley 2025, Ryall 2025, Tunnicliffe 2025, Ronne-Petersen 2024, Guo 2025, Behar-Lagares 2026, Shen 2026, Vlasova 2026, Gerede 2026.\n\n## References\n\n- **Young 2025.** _Role of telomere length and telomerase activity in accelerated cellular aging and major depressive disorder: a systematic review._ Molecular Psychiatry, 2025. DOI: 10.1038/s41380-025-03296-3. PMID: 41053437.\n- **Sasmita 2025.** _Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis._ Exploration of Targeted Anti-tumor Therapy, 2025. DOI: 10.37349/etat.2025.1002289. PMID: 40061142.\n- **Su 2025.** _Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis._ Cell Biology and Toxicology, 2025. DOI: 10.1007/s10565-025-10115-6. PMID: 41286474.\n- **Jaeger 2024.** _A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study._ Nutrients, 2024. DOI: 10.3390/nu16172963. PMID: 39275278.\n- **Yang 2025.** _Determinants of temporal change in telomere length and its associations with chronic complications and mortality in type 2 diabetes: the Fremantle diabetes study phase II._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02832-3. PMID: 40611236.\n- **Ojeda-Rodriguez 2024.** _Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial._ Cardiovascular Diabetology, 2024. DOI: 10.1186/s12933-024-02175-5. PMID: 38493287.\n- **Wolkowitz 2011.** _Leukocyte Telomere Length in Major Depression: Correlations with Chronicity, Inflammation and Oxidative Stress - Preliminary Findings._ PLoS ONE, 2011. DOI: 10.1371/journal.pone.0017837. PMID: 21448457.\n- **Hastings 2024.** _Effect of long‐term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis._ Aging Cell, 2024. DOI: 10.1111/acel.14149. PMID: 38504468.\n- **Fuente 2025.** _Beneficial Effects of a Moderately High-Protein Diet on Telomere Length in Subjects with Overweight or Obesity._ Nutrients, 2025. DOI: 10.3390/nu17020319. PMID: 39861449.\n- **Gemmati 2025.** _LINE-1 Methylation sustains telomere length in pregnant women: effects on pregnancy failure._ Clinical Epigenetics, 2025. DOI: 10.1186/s13148-025-01937-6. PMID: 40702545.\n- **Mutz 2024.** _The duration of lithium use and biological ageing: telomere length, frailty, metabolomic age and all-cause mortality._ GeroScience, 2024. DOI: 10.1007/s11357-024-01142-y. PMID: 38539016.\n- **Farhat 2025.** _Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial._ Nutrients, 2025. DOI: 10.3390/nu17182974. PMID: 41010500.\n- **Ishii 2025.** _Relationship between telomere length and postoperative delirium: a single center prospective observational pilot study._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-10288-4. PMID: 40628895.\n- **Wattanathorn 2025.** _An Anthocyanin-and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms262210911. PMID: 41303396.\n- **Sanchez-Gonzalez 2024.** _Effects of Physical Exercise on Telomere Length in Healthy Adults: Systematic Review, Meta-Analysis, and Meta-Regression._ JMIR Public Health and Surveillance, 2024. DOI: 10.2196/46019. PMID: 38194261.\n- **Wilbourn 2018.** _The relationship between telomere length and mortality risk in non-model vertebrate systems: a meta-analysis._ Philosophical Transactions of the Royal Society B: Biological Sciences, 2018. DOI: 10.1098/rstb.2016.0447. PMID: 29335371.\n- **Murillo-Ortiz 2025.** _Association Between Telomere Shortening and Erythropoietin Resistance in Patients with Chronic Kidney Disease Undergoing Hemodialysis._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26073405. PMID: 40244253.\n- **Ismail 2025.** _Exploring the association between depression and telomere length: A systematic review and meta-analysis._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-07076-5. PMID: 40595131.\n- **Guillen-Parra 2024.** _The relationship between mitochondrial health, telomerase activity and longitudinal telomere attrition, considering the role of chronic stress._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-77279-9. PMID: 39738205.\n- **Liu 2025.** _Platelet-to-lymphocyte ratio and telomere length in older adults: An inverted U-shaped nonlinear relationship: A nationwide cohort study._ Medicine, 2025. DOI: 10.1097/MD.0000000000044188. PMID: 40958330.\n- **Lehodey 2025.** _Telomere dynamics are influenced by sleep, sleep variability and circadian rhythms in older adults with or without alzheimer’s risk._ Alzheimer's Research & Therapy, 2025. DOI: 10.1186/s13195-025-01923-3. PMID: 41345970.\n- **Parikh 2025.** _Associations of Midlife Leukocyte Telomere Length With Measures of Left Atrial Function in Community‐Dwelling Older Adults: The ARIC Study._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2025. DOI: 10.1161/JAHA.124.040459. PMID: 40767284.\n- **Kim 2025.** _Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms._ Nutrients, 2025. DOI: 10.3390/nu17121983. PMID: 40573097.\n- **Liu 2025b.** _A telomere-to-telomere genome assembly coupled with multi-omic data provides insights into the evolution of hexaploid bread wheat._ Nature Genetics, 2025. DOI: 10.1038/s41588-025-02137-x. PMID: 40195562.\n- **Breitling 2016.** _Frailty is associated with the epigenetic clock but not with telomere length in a German cohort._ Clinical Epigenetics, 2016. DOI: 10.1186/s13148-016-0186-5. PMID: 26925173.\n- **Sun 2025.** _Exercise delays aging: evidence from telomeres and telomerase —a systematic review and meta-analysis of randomized controlled trials._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1627292. PMID: 40642293.\n- **Hanley 2025.** _Shorter Telomeres and Faster Telomere Attrition in Individuals With Five Syndromic Forms of Intellectual Disability: A Systematic Review and Meta‐Analysis._ Journal of Intellectual Disability Research, 2025. DOI: 10.1111/jir.13244. PMID: 40274277.\n- **Fu 2024.** _Objective assessment of the association between telomere length, a biomarker of aging, and health screening indicators: A cross-sectional study._ Medicine, 2024. DOI: 10.1097/MD.0000000000038533. PMID: 38875394.\n- **Ryall 2025.** _A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf068. PMID: 40247641.\n- **Xia 2024.** _Associations between weight-adjusted-waist index and telomere length: Results from NHANES: An observational study._ Medicine, 2024. DOI: 10.1097/MD.0000000000037905. PMID: 38669426.\n- **Al-Hawary 2024.** _The association of metabolic syndrome with telomere length as a marker of cellular aging: a systematic review and meta-analysis._ Frontiers in Genetics, 2024. DOI: 10.3389/fgene.2024.1390198. PMID: 39045323.\n- **Tunnicliffe 2025.** _Infection and telomere length: A systematic review._ PLOS One, 2025. DOI: 10.1371/journal.pone.0333107. PMID: 40986533.\n- **Andreikos 2024.** _The Association between Telomere Length and Head and Neck Cancer Risk: A Systematic Review and Meta-Analysis._ International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25169000. PMID: 39201686.\n- **Ronne-Petersen 2024.** _Exploring emotional well-being, spiritual, religious and personal beliefs and telomere length in chronic pain patients—A pilot study with cross-sectional design._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0308924. PMID: 39231146.\n- **Guo 2025.** _Effect of infections, DNA methylation and telomere length on frailty trajectories in hospitalized older patients: the INFRAGEN study protocol._ BMC Geriatrics, 2025. DOI: 10.1186/s12877-025-06194-z. PMID: 40702442.\n- **Behar-Lagares 2026.** _Gender-based differences in telomere attrition and long-term respiratory dysfunction in COVID-19 ICU survivors one year post-infection: implications for aging-associated pulmonary decline._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2025.1681454. PMID: 41567226.\n- **Shen 2026.** _The association of serum levels of vitamin D with leucocyte telomere length, as a marker of biological aging: A meta-analysis._ Medicine, 2026. DOI: 10.1097/MD.0000000000044487. PMID: 41650046.\n- **Vlasova 2026.** _Parental Age Effects on Offspring Telomere Length Across Vertebrates: A Meta‐Analysis._ Molecular Ecology, 2026. DOI: 10.1111/mec.70215. PMID: 41556533.\n- **Gerede 2026.** _A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives._ Medical Sciences, 2026. DOI: 10.3390/medsci14010100. PMID: 41892815.\n- **Sanchez-Gonzalez 2025.** _Effect of Physical Exercise on Telomere Length: Umbrella Review and Meta-Analysis._ JMIR Aging, 2025. DOI: 10.2196/64539. PMID: 39846264.\n\n### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"Evidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Telomere length is widely examined as a biomarker of biological aging, yet the clinical implications of observed associations remain uncertain. We conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes.","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":40,"selected_count":40,"review_like_count":17,"primary_like_count":23,"year_start":2011,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":null,"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/4RSMW","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"4rsmw","osf_url":"https://osf.io/4rsmw/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"4rsmw","url":"https://osf.io/4rsmw/","doi":"10.17605/OSF.IO/4RSMW"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_acbbf4c2352d4ebc","dw_chain_url":"https://provenance.researka.org/artifacts/claim_acbbf4c2352d4ebc/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_acbbf4c2352d4ebc/chain","dw_source_artifact_id":"source_a87df78d5d9a4a95","dw_input_artifact_ids":["source_f026671611f544b6","source_218b3b9fa45c4ee0","source_992dcf0286c14130","source_0efb3acd870b4877","source_29c4b61c05ff4df7","source_7b09ba213a2540dd"],"dw_step_id":"step_dbaa35172f7c4451","dw_step_hash":"bd60fea3b1f2a682d5c73243642bc0c64673f8eb2d0121b530d809fc1184a117","dw_status":"registered","content_hash":"sha256:c177226449a619ef6c04cac19cd800c090db224b43176ccee329bde33b64cc4e","sha256":"sha256:c177226449a619ef6c04cac19cd800c090db224b43176ccee329bde33b64cc4e"},"created_at":"2026-06-04T13:29:54.689556+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Telomere length is widely examined as a biomarker of biological aging, yet the clinical implications of observed associations remain uncertain. We conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_2","claim":"Evidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_3","claim":"This synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_4","claim":"We conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_5","claim":"The current evidence supports telomere length as a reproducible prognostic marker for cancer recurrence and diabetes complications, but its value as a therapeutic target remains unproven; interventions that lengthen telomeres have not yet demonstrated downstream clinical benefit, and mechanistic plausibility alone is insufficient to justify routine clinical application.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_6","claim":"Evidence-abstraction note.** The 40 retained reference papers are not 40 independent primary clinical trials: 40 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_7","claim":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_effects-v06-DAILY-2026-06-04T09-26-23Z-R2`.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_8","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_9","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_10","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_11","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_12","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_13","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_14","claim":"| Contextual Adjacent Evidence | n=23; claims=739 | no extracted directional signal in 19/23 sources | 13 indirect; 10 review | limited corpus depth in this outcome class |","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_15","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_16","claim":"23 included sources were assigned to this outcome class. Directional coding: mixed=1, null=19, unclear=3. Directness coding: indirect=13, review=10.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_17","claim":"5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, review=2.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_18","claim":"3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=2, review=1.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_19","claim":"3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_20","claim":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_21","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_22","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_23","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_24","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_25","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_26","claim":"The curated corpus is dominated by observational cohort designs and systematic reviews of observational data; no large, long-duration randomized controlled trial of telomere-targeted intervention with hard clinical endpoints such as all-cause mortality or incident cardiovascular events was identified within the included sources. Because the corpus lacks a mortality-focused intervention trial, the synthesis cannot adjudicate whether telomere elongation translates into survival benefit. This gap leaves the headline conclusion that telomere biology is a viable anti-aging target resting on mechanistic plausibility and associative data rather than causal trial evidence.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_27","claim":"The evidence base is heavily weighted toward telomere length as a surrogate biomarker, while functional and patient-centered endpoints are sparse. Whether telomere length itself is a valid surrogate or merely a correlate of underlying biological aging processes remains unresolved — a concern consistent with the general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). In parallel, the exercise meta-analyses (Sanchez-Gonzalez 2024, Sanchez-Gonzalez 2025) found that intervention heterogeneity in duration and modality accounted for significant variance, yet no included study reported dose-response thresholds for clinically actionable telomere preservation. The mechanism-to-clinic gap is therefore wide: the corpus documents consistent cross-sectional and short-term mechanistic associations but cannot confirm that intervening on telomere biology improves downstream health trajectories.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_28","claim":"For telomere effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_29","claim":"This synthesis maps 40 included sources on Telomere Effects across 9 outcome classes and 270 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]},{"claim_id":"claim_30","claim":"Across 40 curated reference papers, the evidence base for Telomere Effects shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","citation_support":[],"candidate_sources":[{"study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD.","source_id":"source_1","support_kind":"candidate_source_row"},{"study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance.","source_id":"source_2","support_kind":"candidate_source_row"},{"study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs.","source_id":"source_3","support_kind":"candidate_source_row"},{"study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL.","source_id":"source_4","support_kind":"candidate_source_row"},{"study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%).","source_id":"source_5","support_kind":"candidate_source_row"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","content_hash":"sha256:c177226449a619ef6c04cac19cd800c090db224b43176ccee329bde33b64cc4e","nodes":[{"id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","type":"publication","title":"Research Synthesis: Telomere Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Telomere length is widely examined as a biomarker of biological aging, yet the clinical implications of observed associations remain uncertain. We conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes."},{"id":"claim_2","type":"claim","text":"Evidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_3","type":"claim","text":"This synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation."},{"id":"claim_4","type":"claim","text":"We conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes."},{"id":"claim_5","type":"claim","text":"The current evidence supports telomere length as a reproducible prognostic marker for cancer recurrence and diabetes complications, but its value as a therapeutic target remains unproven; interventions that lengthen telomeres have not yet demonstrated downstream clinical benefit, and mechanistic plausibility alone is insufficient to justify routine clinical application."},{"id":"claim_6","type":"claim","text":"Evidence-abstraction note.** The 40 retained reference papers are not 40 independent primary clinical trials: 40 are review, indirect, or mechanistic source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_7","type":"claim","text":"This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_effects-v06-DAILY-2026-06-04T09-26-23Z-R2`."},{"id":"claim_8","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_9","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_10","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_11","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_12","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_13","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_14","type":"claim","text":"| Contextual Adjacent Evidence | n=23; claims=739 | no extracted directional signal in 19/23 sources | 13 indirect; 10 review | limited corpus depth in this outcome class |"},{"id":"claim_15","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_16","type":"claim","text":"23 included sources were assigned to this outcome class. Directional coding: mixed=1, null=19, unclear=3. Directness coding: indirect=13, review=10."},{"id":"claim_17","type":"claim","text":"5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, review=2."},{"id":"claim_18","type":"claim","text":"3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=2, review=1."},{"id":"claim_19","type":"claim","text":"3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3."},{"id":"claim_20","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2."},{"id":"claim_21","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_22","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_23","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1."},{"id":"claim_24","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1."},{"id":"claim_25","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_26","type":"claim","text":"The curated corpus is dominated by observational cohort designs and systematic reviews of observational data; no large, long-duration randomized controlled trial of telomere-targeted intervention with hard clinical endpoints such as all-cause mortality or incident cardiovascular events was identified within the included sources. Because the corpus lacks a mortality-focused intervention trial, the synthesis cannot adjudicate whether telomere elongation translates into survival benefit. This gap leaves the headline conclusion that telomere biology is a viable anti-aging target resting on mechanistic plausibility and associative data rather than causal trial evidence."},{"id":"claim_27","type":"claim","text":"The evidence base is heavily weighted toward telomere length as a surrogate biomarker, while functional and patient-centered endpoints are sparse. Whether telomere length itself is a valid surrogate or merely a correlate of underlying biological aging processes remains unresolved — a concern consistent with the general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). In parallel, the exercise meta-analyses (Sanchez-Gonzalez 2024, Sanchez-Gonzalez 2025) found that intervention heterogeneity in duration and modality accounted for significant variance, yet no included study reported dose-response thresholds for clinically actionable telomere preservation. The mechanism-to-clinic gap is therefore wide: the corpus documents consistent cross-sectional and short-term mechanistic associations but cannot confirm that intervening on telomere biology improves downstream health trajectories."},{"id":"claim_28","type":"claim","text":"For telomere effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_29","type":"claim","text":"This synthesis maps 40 included sources on Telomere Effects across 9 outcome classes and 270 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_30","type":"claim","text":"Across 40 curated reference papers, the evidence base for Telomere Effects shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"source_1","type":"source","study":"Young 2025","year":2025,"doi":"10.1038/s41380-025-03296-3","url":"https://doi.org/10.1038/s41380-025-03296-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This review synthesizes findings from 30 studies conducted over the past 15 years, examining alterations in telomere length (TL) and telomerase activity (TA) in individuals with MDD compared to healthy controls. Author, Year Sample size: MDD / controls Female (%): MDD/ controls Duration of study Attrition rate Main findings: TL in MDD Other findings Ochi, 2023 [ 10 ] 10.1038/s41380-023-02263-0 33 / 20 78.8% / 40% - - LTL was significantly reduced in adolescents with MDD."},{"id":"source_2","type":"source","study":"Sasmita 2025","year":2025,"doi":"10.37349/etat.2025.1002289","url":"https://doi.org/10.37349/etat.2025.1002289","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Shorter telomere length was significantly associated with increased recurrence risk (DFS/RFS) (pooled HR: 1.97; 95% CI: 1.04-3.74, P = 0.039), indicating a nearly twofold increase in risk. Trends toward worse OS (pooled HR: 1.60; 95% CI: 0.90-2.86, P = 0.110) and DSS (pooled HR: 1.09; 95% CI: 0.80-1.49, P = 0.565) were observed, but did not reach statistical significance."},{"id":"source_3","type":"source","study":"Su 2025","year":2025,"doi":"10.1007/s10565-025-10115-6","url":"https://doi.org/10.1007/s10565-025-10115-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"This PRISMA-guided meta-analysis evaluated 8 randomized controlled trials (RCTs, n = 750 participants; mean age 63.3 years) assessing TA-65’s effects on telomere dynamics, functional aging indices, and safety outcomes. TA-65 supplementation induced moderate telomere elongation (SMD = 0.47, 95% CI: 0.31-0.62; p < 0.00001), with amplified effects in adults > 60 years (SMD = 0.63 vs."},{"id":"source_4","type":"source","study":"Jaeger 2024","year":2024,"doi":"10.3390/nu16172963","url":"https://doi.org/10.3390/nu16172963","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In this study, we conducted a randomized, double-blind, placebo-controlled trial over six months to compare the effects of the Astragalus-based supplement versus a placebo on telomere length (TL) in 40 healthy volunteers (mean age 56.1 ± 6.0 years). Subjects taking the Astragalus-based supplement exhibited significantly longer median TL ( p = 0.01) and short TL ( p = 0.004), along with a lower percentage of short telomeres, over the six-month period, while the placebo group showed no change in TL."},{"id":"source_5","type":"source","study":"Yang 2025","year":2025,"doi":"10.1186/s12933-025-02832-3","url":"https://doi.org/10.1186/s12933-025-02832-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"We aimed to identify the associates of rTL change over 4 years (∆rTL), and to investigate whether rTL and ∆rTL are associated with complications and mortality in adults with type 2 diabetes from the Australian observational community-based Fremantle Diabetes Study Phase II (FDS2). The rTL change (∆rTL; % change/year) was categorised as Shortened (< - 2.69%), Unchanged (- 2.69% to + 2.69%) or Lengthened (> + 2.69%)."},{"id":"source_6","type":"source","study":"Ojeda-Rodriguez 2024","year":2024,"doi":"10.1186/s12933-024-02175-5","url":"https://doi.org/10.1186/s12933-024-02175-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"In brief, eligible patients included men and women between the ages of 20 and 75 years, who had established CHD, were free of clinical coronary events in the previous six months, were able to follow a long-term dietary intervention, and had no severe illnesses or an expected life expectancy lower than the length of the study. Every year, T2DM incidence was assessed according to the ADA T2DM criteria: fasting plasma glucose ≥ 126 mg/dL or 2 h plasma glucose in the 75 g oral glucose tolerance test ≥ 200 mg/dL or glycosylated haemoglobin (HbA1c) levels ≥ 6.5%."},{"id":"source_7","type":"source","study":"Fuente 2025","year":2025,"doi":"10.3390/nu17020319","url":"https://doi.org/10.3390/nu17020319","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Both groups experienced significant improvements in anthropometric and biochemical parameters after the dietary intervention ( p < 0.001). The MHP group showed an increase in TL (+0.16 ± 0.13) compared to the LF group (-0.05 ± 0.13) in multiple-adjusted models ( p = 0.016)."},{"id":"source_8","type":"source","study":"Gemmati 2025","year":2025,"doi":"10.1186/s13148-025-01937-6","url":"https://doi.org/10.1186/s13148-025-01937-6","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Telomere length (TL; T/S) and LINE-1 methylation (LINE-1; %) have been assessed in a cohort of 242 pregnant women by comparing spontaneous early miscarriage (EPL, n = 129) with voluntary interruption (VPI, n = 113). Telomere size and LINE-1 methylation rate drastically decreased as the age of women increased ( P < 0.000001) with EPL group having lower values (T/S: 322.6 ± 142.0 versus 455.0 ± 290.6; P < 0.000001 and LINE-1 %: 81.66 ± 4.2 versus 86.01 ± 3.7; P < 0.000001) also characterized by stronger age-dependent lowering compared to VPI ( P = 0.00035 and P < 0.000001, respectively)."},{"id":"source_9","type":"source","study":"Hastings 2024","year":2024,"doi":"10.1111/acel.14149","url":"https://doi.org/10.1111/acel.14149","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"CALERIE™ randomized healthy, nonobese men and premenopausal women (age 21-50y; BMI 22.0-27.9 kg/m 2 ), to 25% CR or ad‐libitum (AL) control (2:1) for 2 years. In humans, cross‐sectional data showing an inverse association between energy intake and TL provide indirect support of similar CR intervention effects (Kark et al., 2012 ), as does evidence of TL lengthening observed in obese individuals maintaining 5% or greater weight loss over a 1 year period (Mason et al., 2018 )."},{"id":"source_10","type":"source","study":"Mutz 2024","year":2024,"doi":"10.1007/s11357-024-01142-y","url":"https://doi.org/10.1007/s11357-024-01142-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"There was no evidence that the number of prescriptions ( β = - 0.022, 95% CI - 0.081 to 0.037, p = 0.47), the total duration of use ( β = - 0.005, 95% CI - 0.023 to 0.013, p = 0.57) or the duration of the first prescription period ( β = - 0.018, 95% CI - 0.051 to 0.015, p = 0.29) correlated with telomere length. A frailty Index was derived from health deficits that met the following criteria: indicators of poor health, more prevalent in older individuals, neither rare nor universal, covering multiple areas of functioning and available for ≥ 80% of participants [ 27 ]."},{"id":"source_11","type":"source","study":"Farhat 2025","year":2025,"doi":"10.3390/nu17182974","url":"https://doi.org/10.3390/nu17182974","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Objective : To investigate the effects of pomegranate extract on telomere length and serum IGF-1 levels in older adults aged 55-70 years. Methods : Participants took part in a two-arm double-blind parallel trial, receiving either placebo capsules (maltodextrin) or pomegranate extract (740 mg) daily for 12 weeks."},{"id":"source_12","type":"source","study":"Ishii 2025","year":2025,"doi":"10.1038/s41598-025-10288-4","url":"https://doi.org/10.1038/s41598-025-10288-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"However, multivariable analyses revealed that preoperative TL ≥ 309,110 RLU/µg DNA significantly associated with decreased POD risk after adjusting for age (aOR: 0.132; 95% CI: 0.022-0.799; p = 0.047) and preoperative MMSE score (aOR: 0.153; 95% CI: 0.028-0.851; p = 0.032). We included patients older than 65 years who underwent surgery and were expected to stay in the intensive care unit (ICU) for 2 days or more after surgery at Hirosaki University Hospital."},{"id":"source_13","type":"source","study":"Wattanathorn 2025","year":2025,"doi":"10.3390/ijms262210911","url":"https://doi.org/10.3390/ijms262210911","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"A total of 90 male and female volunteers (45-65 years old) participated in a 3-arm randomized, double blinded, placebo-controlled parallel study for 12 weeks. Cognition, facial wrinkles, atherogenic index in plasma (AIP), telomere length, telomerase, oxidative stress and inflammatory markers, together with safety parameters, were assessed every 6 weeks until the end of the study and compared to the baseline data."},{"id":"source_14","type":"source","study":"Sanchez-Gonzalez 2024","year":2024,"doi":"10.2196/46019","url":"https://doi.org/10.2196/46019","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Meta-analysis showed that exercise did not significantly increase telomere length compared with the control intervention (mean difference=0.0058, 95% CI -0.05 to 0.06; P =.83). Subgroup analysis suggested that high-intensity interventional exercise significantly increased telomere length compared with the control intervention in healthy individuals (mean difference=0.15, 95% CI 0.03-0.26; P =.01)."},{"id":"source_15","type":"source","study":"Murillo-Ortiz 2025","year":2025,"doi":"10.3390/ijms26073405","url":"https://doi.org/10.3390/ijms26073405","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Mean hemoglobin levels were lower in the erythropoietin resistance group (8.8 ± 1.67 vs. Differences were observed in hematocrit and albumin levels, which were lower in patients with erythropoietin resistance, while PTH levels were higher in this group (788 ± 538.47 vs."},{"id":"source_16","type":"source","study":"Ismail 2025","year":2025,"doi":"10.1038/s41598-025-07076-5","url":"https://doi.org/10.1038/s41598-025-07076-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Our analysis revealed a significant association between depression and telomere length, with a Cohen’s d effect size of -0.354 (p-value < 0.0001, I 2 = 80%). Specifically, telomere length data from MDD subjects ( n = 15) and controls ( n = 44) were utilized to calculate effect sizes for inclusion in this meta-analysis."},{"id":"source_17","type":"source","study":"Guillen-Parra 2024","year":2024,"doi":"10.1038/s41598-024-77279-9","url":"https://doi.org/10.1038/s41598-024-77279-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Here we show that both chronic stress exposure and lower MHI independently predicted decreases in telomerase activity over the subsequent 9 months. We test relations between baseline MHI to the changes over time in telomerase enzymatic activity, and to changes in telomere length during a period of 9 months."},{"id":"source_18","type":"source","study":"Liu 2025","year":2025,"doi":"10.1097/MD.0000000000044188","url":"https://doi.org/10.1097/MD.0000000000044188","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Threshold effect analysis identified a breakpoint at PLR Log = 5.564, where TeloMean significantly increased with PLR Log when below this threshold (β1 = 0.034, 95% CI: 0.012-0.057, P = .003), but decreased when PLR Log exceeded this threshold (β2 = -0.115, 95% CI: -0.221 to -0.009, P = .033). This association was more pronounced in participants aged 66 to 74 years ( P for interaction = .005)."},{"id":"source_19","type":"source","study":"Lehodey 2025","year":2025,"doi":"10.1186/s13195-025-01923-3","url":"https://doi.org/10.1186/s13195-025-01923-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Although sleep disturbances have been linked to shorter telomere length (TL), the effects of sleep, its variability, and circadian rhythms on telomere dynamics (over 18 months) remain unknown. We hypothesize that poorer sleep and higher variability in sleep and circadian rhythms at baseline will predict 50th and 20th percentile TL shortening, as well as an increased load of CST over 18 months."},{"id":"source_20","type":"source","study":"Parikh 2025","year":2025,"doi":"10.1161/JAHA.124.040459","url":"https://doi.org/10.1161/JAHA.124.040459","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In models adjusted for chronological age at blood draw for LTL measurement, whole genome sequencing platform, visit for blood draw, cardiometabolic risk factors, and coronary heart disease, longer LTL was associated with greater (better) LA contractile strain (β=0.29 [95% CI, 0.10-0.47]; P =0.006) and LA reservoir strain (β=0.35 [95% CI, 0.12-0.59]; P =0.003) but not LA conduit strain (β=0.05 [95% CI, -0.12 to 0.21]; P =0.575). 31 Diabetes was defined as a glycated hemoglobin A 1c value of ≥6.5% at visit 5 (in primary analyses), or fasting blood glucose of ≥126 mg/dL or nonfasting blood glucose of ≥200 mg/dL in midlife, at the time of blood draw (in sensitivity analyses), as well as a self‐reported physician diagnosis of diabetes, or use of antidiabetic medication in the past 2 weeks (in both the primary and sensitivity analyses)."},{"id":"source_21","type":"source","study":"Kim 2025","year":2025,"doi":"10.3390/nu17121983","url":"https://doi.org/10.3390/nu17121983","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"The HF supplementation group ( n = 17) was instructed to take a powdered HF supplement (900 mg/day), while controls ( n = 19) were to take a cornstarch placebo (900 mg/day). Results: The HF supplementation group exhibited significantly improved hydration scores compared to the control group; the mean changes (follow-up measure-baseline measure) [standard deviation] in hydration scores over 6 months were 1.71 [8.18] and -3.00 [8.42] for the supplementation group and control group, respectively ( p < 0.05) (Cohen’s d = 0.57)."},{"id":"source_22","type":"source","study":"Liu 2025b","year":2025,"doi":"10.1038/s41588-025-02137-x","url":"https://doi.org/10.1038/s41588-025-02137-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"First, Benchmarking Universal Single-Copy Ortholog (BUSCO 31 v.5.6.1) was used to compare the assembly against a database containing 4,896 core Poales genes, resulting in 99.96% completeness, higher than the 99.4% completeness of the Kariega assembly 11 (Supplementary Table 4 ). Short PCR-free, HiFi and ONT UL reads were mapped to the CS-IAAS genome, which generated mapping rates of 99.98%, 100% and 100%, respectively, with corresponding genome coverages of 99.88%, 99.98% and 100%, respectively (Supplementary Table 6 and Extended Data Fig."},{"id":"source_23","type":"source","study":"Sun 2025","year":2025,"doi":"10.3389/fphys.2025.1627292","url":"https://doi.org/10.3389/fphys.2025.1627292","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Exercise intervention significantly maintained TL (SMD = 0.59, 95% CI: 0.14-1.06, P = 0.01) and enhanced TA (SMD = 0.35, 95% CI: 0.20-0.51, P < 0.00001). Aerobic exercise (AE) consistently increased TA (SMD = 0.33, P = 0.0001), while resistance exercise (RE) showed non-significant trends (SMD = 0.16, P = 0.43)."},{"id":"source_24","type":"source","study":"Hanley 2025","year":2025,"doi":"10.1111/jir.13244","url":"https://doi.org/10.1111/jir.13244","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"For example, people with intellectual disability suffered a higher death rate from potentially avoidable diseases (31%) compared with the general population (17%), circulatory disease being the highest contributor (Trollor et al. The meta‐analysis included fourteen studies comprised of 16 comparisons of leukocyte telomere length between individuals with intellectual disability and healthy controls ( N = 366 and 481, respectively)."},{"id":"source_25","type":"source","study":"Ryall 2025","year":2025,"doi":"10.1093/gerona/glaf068","url":"https://doi.org/10.1093/gerona/glaf068","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Relative to individuals with below-average VO 2max based on age- and sex-adjusted norms, fit participants with relative VO 2max values in the 70th percentile or higher possessed longer telomeres (standardized mean difference [95% confidence interval {CI}]: 0.36 [0.14-0.59], p = .002). A similar difference was observed between individuals with below-average VO 2max and those above the 90th percentile (0.28 [0.03-0.53], p = .03)."},{"id":"source_26","type":"source","study":"Fu 2024","year":2024,"doi":"10.1097/MD.0000000000038533","url":"https://doi.org/10.1097/MD.0000000000038533","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Interestingly, telomere length was strongly correlated only with the renal indicators eGFR ( P < .001), CYS-C ( P < .001), and SCR ( P < .001). Multifactorial stepwise regression analysis was conducted using SPSS 26 software (IBM: Chicago), with an inclusion criterion of P < .05 to determine significant factors influencing telomere length."},{"id":"source_27","type":"source","study":"Xia 2024","year":2024,"doi":"10.1097/MD.0000000000037905","url":"https://doi.org/10.1097/MD.0000000000037905","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"In the fully adapted model, a significant adverse association of WWI with telomere length was detected [β = -0.02, 95% CI: (-0.03, -0.00), P value = 0.01]. We also discovered an inverted U-shaped curve linking WWI and telomere length, with a conspicuous inflection point of 10.07 cm/√kg."},{"id":"source_28","type":"source","study":"Al-Hawary 2024","year":2024,"doi":"10.3389/fgene.2024.1390198","url":"https://doi.org/10.3389/fgene.2024.1390198","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"No significant difference in mean TL was found between patients with and without MetS (SMD = -0.03, 95%CI = -0.17 to 0.10), with a significant heterogeneity across the studies ( I 2 = 89.7.0%, p ≤ 0.001). The inclusion criteria for the meta-analysis were as follows: 1) cross-sectional, cohort, and case-control studies that reported the relation of MetS (exposure) to TL (outcome) in adults, 2) the studies needed to report means and standard deviations (SD) of TL in patients with and without MetS or provided sufficient data to obtain standardized regression coefficients (β) along with their corresponding 95% confidence intervals (CI) for the association between MetS and TL."},{"id":"source_29","type":"source","study":"Tunnicliffe 2025","year":2025,"doi":"10.1371/journal.pone.0333107","url":"https://doi.org/10.1371/journal.pone.0333107","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"HIV was the most frequently studied infection (35 studies), with 79% (excluding overlapping samples) reporting an association between HIV and reduced TL or increased telomere attrition. Instead, we presented forest plots for infections with at least three studies that reported the same type of effect estimate (e.g., difference in mean telomere lengths) with 95% confidence intervals, or where both the effect estimate and its 95% confidence interval could be calculated from the available data."},{"id":"source_30","type":"source","study":"Behar-Lagares 2026","year":2026,"doi":"10.3389/fimmu.2025.1681454","url":"https://doi.org/10.3389/fimmu.2025.1681454","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"At follow-up, women who had undergone pronation and had shorter RTL continued to show a higher prevalence of symptoms [aAMR= 0.66 (0.58-0.76); p< 0.001]. The stratified longitudinal analysis of the RTL change one-year post-ICU discharge ( Figure 1 ) showed no significant change in RTL for both men and women overall (p=0.302 and p=0.104, respectively)."},{"id":"source_31","type":"source","study":"Shen 2026","year":2026,"doi":"10.1097/MD.0000000000044487","url":"https://doi.org/10.1097/MD.0000000000044487","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Heterogeneity was indicated if the I 2 value exceeded 50% or the Cochran-Q P -value was <.1. [ 15 , 16 ] A random-effects model with DerSimonian and Laird was applied to pool the data. [ 17 ] The prediction interval was calculated to estimate the range in which the true effect size of a future study is expected to fall, taking into account both the overall effect and between-study heterogeneity. [ 18 ] Subgroup analyses were conducted by population (adults [aged ≥ 18 years] versus children [aged <18 years]), sample size (≥1000 vs <1000 participants), gender, BMI category (≥25 vs <25 kg/m2), vitamin D status (≥30 vs <30 ng/mL), method of TL assessment (qPCR vs Southern blot), and covariate adjustment (yes vs no) to identify potential sources of heterogeneity. The pooled analysis of all available studies found a positive correlation between serum 25(OH)D levels and LTL (β = 0.04, 95% CI = "},{"id":"source_32","type":"source","study":"Guo 2025","year":2025,"doi":"10.1186/s12877-025-06194-z","url":"https://doi.org/10.1186/s12877-025-06194-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Frailty status will be evaluated through the CFS and Frailty Index at admission (referring to the 2 weeks before hospitalization), hospital discharge, and after 3 months. Participants will be selected based on the following criteria: age ≥ 70 years, non-frailty or mild frailty status before admission (CFS < 6), and confirmed diagnosis of acute infectious diseases at the time of hospital admission or during the hospital stay, according to specific ICD-9 codes, with or without a systemic inflammatory response."},{"id":"source_33","type":"source","study":"Andreikos 2024","year":2024,"doi":"10.3390/ijms25169000","url":"https://doi.org/10.3390/ijms25169000","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"The odds ratios (ORs) and 95% confidence intervals (CIs) were used to ascertain the strength of the association. Our analysis found a significant relationship between short TL and increased HNC risk (OR 1.38, 95% CI: 1.10-1.73, p = 0.005), while significant heterogeneity among the studies was noted."},{"id":"source_34","type":"source","study":"Ronne-Petersen 2024","year":2024,"doi":"10.1371/journal.pone.0308924","url":"https://doi.org/10.1371/journal.pone.0308924","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"With 19-50% of the European population affected, chronic pain is common, and in the female population the prevalence is at least 10% higher than among males [ 2 , 6 , 7 ]. Inclusion criteria were ICD-10 M79, OR chronic pain (>3 months) in neck/shoulders and/or lower back or generalized pain (e.g. fibromyalgia), ≥18 years of age, fluent in Swedish, resident in Stockholm, Sörmland or Östergötland county councils."},{"id":"source_35","type":"source","study":"Vlasova 2026","year":2026,"doi":"10.1111/mec.70215","url":"https://doi.org/10.1111/mec.70215","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"Studies were included if they (1) were original research articles; (2) used a vertebrate; (3) used continuous separate paternal and/or maternal age at conception as explanatory variables (instead of categorical age groups or a measure of combined parental ages); (4) measured offspring telomere length as the response variable; and (5) reported effect sizes with associated standard errors (SE) or 95% confidence intervals (CI), or reported correlation coefficients, or provided raw data ( n = 1) to reconstruct the statistical model described in the text to calculate the effect size and corresponding error (Figure 1 ). While in the human subset we found no effect of offspring age at sampling, in the non‐human vertebrate subset, offspring that were measured as juveniles or as juveniles and adults had borderline more negative parental age effects ( p = 0.05) on offspring telomere length than of"},{"id":"source_36","type":"source","study":"Gerede 2026","year":2026,"doi":"10.3390/medsci14010100","url":"https://doi.org/10.3390/medsci14010100","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Cecati et al. demonstrated a 40% reduction in TL in placental samples from women with PE compared to healthy controls [ 30 ] while Manna et al. reported higher telomere lengths in women with preeclampsia, although the difference was not statistically significant [ 31 ]. Both total antioxidant status (TAS) and total oxidant status (TOS) were elevated in cord blood and placental tissue ( p < 0.05)."},{"id":"source_37","type":"source","study":"Sanchez-Gonzalez 2025","year":2025,"doi":"10.2196/64539","url":"https://doi.org/10.2196/64539","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"The number of weeks of intervention explained part of this heterogeneity (Q_B=8.25; P =.004), with higher effect sizes found in studies with an intervention of less than 30 weeks."},{"id":"source_38","type":"source","study":"Wolkowitz 2011","year":2011,"doi":"10.1371/journal.pone.0017837","url":"https://doi.org/10.1371/journal.pone.0017837","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"However, telomere length was significantly inversely correlated with lifetime depression exposure, even after controlling for age (p<0.05). Average telomere length in the depressed subjects who were above the median of lifetime depression exposure (≥9.2 years' cumulative duration) was 281 base pairs shorter than that in controls (p<0.05), corresponding to approximately seven years of “accelerated cell aging.” Telomere length was inversely correlated with oxidative stress in the depressed subjects (p<0.01) and in the controls (p<0.05) and with inflammation in the depressed subjects (p<0.05)."},{"id":"source_39","type":"source","study":"Wilbourn 2018","year":2018,"doi":"10.1098/rstb.2016.0447","url":"https://doi.org/10.1098/rstb.2016.0447","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level","excerpt":"Indeed, most studies read in full were excluded because suitable data on survival of individuals were lacking, but we also excluded three studies that reported an association between TL and survival but in which fewer than five individuals died (<10% of study population), as power to detect TL-mortality risk relationships would be extremely limited in such cases (see electronic supplementary material, table S1). We extracted the following moderator variables for each study: TL measurement method (TRF or qPCR), the age group of the study animals (categorized as ‘young’ if ≤1 year and ‘adult’ if >1 year), the length of the follow-up period in years after TL measurement, and the log transformation of each species' maximum recorded lifespan (from the AnAge database: http://genomics.senescence.info/species/ )."},{"id":"source_40","type":"source","study":"Breitling 2016","year":2016,"doi":"10.1186/s13148-016-0186-5","url":"https://doi.org/10.1186/s13148-016-0186-5","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary","excerpt":"No correlation of epigenetic age acceleration with telomere length was found in our study ( p = 0.63). After discounting subjects with missing data on telomere length, a total of 1820 participants could be included in the present analysis (969 (97 %) of substudy 1; 851 (98 %) of substudy 2)."}],"edges":[{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_1","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_2","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_3","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_4","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_5","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_6","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_7","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_8","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_9","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_10","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_11","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_12","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_13","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_14","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_15","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_16","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_17","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_18","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_19","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_20","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_21","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_22","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_23","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_24","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_25","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_26","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_27","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_28","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_29","type":"contains_claim"},{"from":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","to":"claim_30","type":"contains_claim"}],"screening":{"identified":40,"screened":40,"excluded":0,"included":40,"included_or_retained":40,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"40 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","screening":{"identified":40,"screened":40,"excluded":0,"included":40,"included_or_retained":40,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"40 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Evidence-honesty note: 35/40 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Telomere Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Telomere length is widely examined as a biomarker of biological aging, yet the clinical implications of observed associations remain uncertain. We conducted a structured evidence synthesis of 40 accepted studies spanning systematic reviews, meta-analyses, and primary trials, applying transparent inclusion criteria and audit-trail documentation to map telomere-length associations across mortality, cardiometabolic, immune-inflammatory, and contextual outcomes.","The current evidence supports telomere length as a reproducible prognostic marker for cancer recurrence and diabetes complications, but its value as a therapeutic target remains unproven; interventions that lengthen telomeres have not yet demonstrated downstream clinical benefit, and mechanistic plausibility alone is insufficient to justify routine clinical application.","23 included sources were assigned to this outcome class. Directional coding: mixed=1, null=19, unclear=3. Directness coding: indirect=13, review=10.","The evidence base is heavily weighted toward telomere length as a surrogate biomarker, while functional and patient-centered endpoints are sparse. Whether telomere length itself is a valid surrogate or merely a correlate of underlying biological aging processes remains unresolved — a concern consistent with the general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). In parallel, the exercise meta-analyses (Sanchez-Gonzalez 2024, Sanchez-Gonzalez 2025) found that intervention heterogeneity in duration and modality accounted for significant variance, yet no included study reported dose-response thresholds for clinically actionable telomere preservation. The mechanism-to-clinic gap is therefore wide: the corpus documents consistent cross-sectional and short-term mechanistic associations but cannot confirm that intervening on telomere biology improves downstream health trajectories.","For telomere effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 40 curated reference papers, the evidence base for Telomere Effects shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nYoung 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSasmita 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nJaeger 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nYang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nOjeda-Rodriguez 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nFuente 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGemmati 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nHastings 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMutz 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nFarhat 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nIshii 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWattanathorn 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSanchez-Gonzalez 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nMurillo-Ortiz 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nIsmail 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nGuillen-Parra 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLiu 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLehodey 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nParikh 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nKim 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLiu 2025b,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSun 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nHanley 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nRyall 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nFu 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nXia 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAl-Hawary 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nTunnicliffe 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nBehar-Lagares 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nShen 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nGuo 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAndreikos 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nRonne-Petersen 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nVlasova 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nGerede 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSanchez-Gonzalez 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nWolkowitz 2011,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nWilbourn 2018,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nBreitling 2016,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"33f96cb2-6b51-49e7-9157-6e5c78662dc1","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Young 2025","doi":"10.1038/s41380-025-03296-3","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sasmita 2025","doi":"10.37349/etat.2025.1002289","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Su 2025","doi":"10.1007/s10565-025-10115-6","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Jaeger 2024","doi":"10.3390/nu16172963","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Yang 2025","doi":"10.1186/s12933-025-02832-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ojeda-Rodriguez 2024","doi":"10.1186/s12933-024-02175-5","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Fuente 2025","doi":"10.3390/nu17020319","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Gemmati 2025","doi":"10.1186/s13148-025-01937-6","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Hastings 2024","doi":"10.1111/acel.14149","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Mutz 2024","doi":"10.1007/s11357-024-01142-y","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Farhat 2025","doi":"10.3390/nu17182974","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ishii 2025","doi":"10.1038/s41598-025-10288-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wattanathorn 2025","doi":"10.3390/ijms262210911","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sanchez-Gonzalez 2024","doi":"10.2196/46019","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Murillo-Ortiz 2025","doi":"10.3390/ijms26073405","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Ismail 2025","doi":"10.1038/s41598-025-07076-5","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Guillen-Parra 2024","doi":"10.1038/s41598-024-77279-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Liu 2025","doi":"10.1097/MD.0000000000044188","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Lehodey 2025","doi":"10.1186/s13195-025-01923-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Parikh 2025","doi":"10.1161/JAHA.124.040459","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Kim 2025","doi":"10.3390/nu17121983","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Liu 2025b","doi":"10.1038/s41588-025-02137-x","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sun 2025","doi":"10.3389/fphys.2025.1627292","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Hanley 2025","doi":"10.1111/jir.13244","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ryall 2025","doi":"10.1093/gerona/glaf068","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Fu 2024","doi":"10.1097/MD.0000000000038533","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Xia 2024","doi":"10.1097/MD.0000000000037905","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Al-Hawary 2024","doi":"10.3389/fgene.2024.1390198","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Tunnicliffe 2025","doi":"10.1371/journal.pone.0333107","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Behar-Lagares 2026","doi":"10.3389/fimmu.2025.1681454","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Shen 2026","doi":"10.1097/MD.0000000000044487","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Guo 2025","doi":"10.1186/s12877-025-06194-z","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Andreikos 2024","doi":"10.3390/ijms25169000","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ronne-Petersen 2024","doi":"10.1371/journal.pone.0308924","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Vlasova 2026","doi":"10.1111/mec.70215","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Gerede 2026","doi":"10.3390/medsci14010100","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sanchez-Gonzalez 2025","doi":"10.2196/64539","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Wolkowitz 2011","doi":"10.1371/journal.pone.0017837","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Wilbourn 2018","doi":"10.1098/rstb.2016.0447","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Breitling 2016","doi":"10.1186/s13148-016-0186-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}}]}